**CUMULATIVE ANTIMICROBIAL SUSCEPTIBILITY REPORT**

January 1, 2022 – December 31, 2022

Prepared by T. Canonica, PharmD

*Antimicrobial Stewardship Program Manager*

Please note the following comments:

* All data is reported as percent fully susceptible
* First isolate per patient per organism is counted in the antibiogram
* 30 organisms are required to report susceptibilities on an antibiogram per CLSI guidelines. Some organisms were included in despite less than 30 organisms isolated
* When treating UTIs, cefazolin can be used to predict results for the following oral agents: cephalexin (Keflex) and cefpodoxime (Vantin)
* Gentamicin susceptibilities for enterococcus are for gram-positive synergy
* Non-urine Coagulase-negative Staphylococcus includes: *S. capitis, S. cohnii,*  *S. epidermidis, S. haemolyticus, S. hominis, S. lugdunensis, and S. saprophyticus, S. warneri*
* Urine Coagulase-negative *staphylococcus* includes: *S. epidermidis, S. haemolyticus, S. lugdunensis, and S. saprophyticus*
* Key: ESBL: Extended-spectrum beta-lactamase; CR: Carbapenem resistant; MR: Methicillin resistant; NA: Not available; R: Intrinsic resistance

**Non-Urine Culture Antibiogram**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|   | # Isolates | Ampicillin | Cefazolin | Ceftriaxone | Ertapenem | Piperacillin/ tazobactam | Cefepime | Ciprofloxacin | Levofloxacin | Gentamicin | Oxacillin | Sulfamethoxazole/ trimethoprim | Clindamycin | Doxycycline | Vancomycin | Linezolid | Daptomycin |
| **Gram negative** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| *Enterobacter cloacae complex* | 29 | R | R | R | 93 | R | 100 | 97 | 97 | 100 | R | NA | R | R | R | R | R |
| *Escherichia coli*  (ESBL 8%) | 49 | 53 | NA | 92 | 100 | 100 | 92 | 59 | 71 | 96 | R | NA | R | R | R | R | R |
| *Klebsiella pneumoniae* (ESBL 20%) | 30 | R | NA | 80 | 100 | 90 | 80 | 70 | 70 | 83 | R | NA | R | R | R | R | R |
| *Proteus mirabilis* | 37 | 69 | NA | 76 | 96 | 95 | 76 | 78 | 78 | 92 | R | NA | R | R | R | R | R |
| *Pseudomonas aeruginosa (*CR 5%) | 61 | R | R | R | R | 98 | 87 | 75 | 69 | 93 | R | R | R | R | R | R | R |
| **Gram positive** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| *Enterococcus faecalis* (VRE 0%) | 29 | 100 | R | R | R | 100 | R | NA | NA | 79 | NA | R | R | R | 100 | 100 | 100 |
| *Staphylococcus aureus* | 242 | R | 64 | NA | NA | NA | NA | NA | NA | R | 64 | 96 | 79 | 96 | 100 | 100 | 100 |
| MSSA (36%) | 87 | R | 100 | NA | NA | NA | NA | NA | NA | R | 100 | 96 | 79 | 99 | 100 | 100 | 100 |
| MRSA *(64%)* | 155 | R | R | NA | NA | NA | NA | NA | NA | R | R | 90 | 67 | 93 | 100 | 100 | 100 |
| Coagulase-negative *staphylococcus* | 88 | R | 48 | NA | NA | NA | NA | NA | NA | R | 48 | 72 | 84 | 82 | 99 | 98 | 70 |
| *Staphylococcus epidermitis (MR 52%)* | 49 |  | 41 | NA | NA | NA | NA | NA | NA | R | 41 | 57 | 57 | 82 | 100 | 100 | 100 |

**Urine Culture Antibiogram**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|   | # Isolates | Ampicillin | Amoxicillin/ clavulanate | Cefazolin | Ceftriaxone | Ciprofloxacin | Gentamicin | Levofloxacin | Nitrofurantoin | Sulfamethoxazole/trimethoprim | Oxacillin | Vancomycin |
| **Gram negative** |  |  |  |  |  |  |  |  |  |  |  |  |
| *Enterobacter cloacae complex* | 44 | R | R | R | R | 93 | 100 | 91 | 50 | 84 | R | R |
| *Escherichia coli*  (ESBL 11%) | 388 | 51 | 87 | 85 | 88 | 75 | 91 |  | 98 | 77 | R | R |
| *Klebsiella oxytoca (CR 2%)* | 43 | R | 91 | 86 | 88 | 93 | 93 | 91 | 84 | 86 | R | R |
| *Klebsiella pneumoniae* (ESBL 9%) | 102 | R | 83 | 88 | 90 | 88 | 94 | 83 | 48 | 87 | R | R |
| *Proteus mirabilis (CR 5%)* | 104 | 76 | 83 | 71 | 72 | 78 | 90 | 79 | R | 81 | R | R |
| *Pseudomonas aeruginosa (CR 3%)* | 86 | R | R | R | R | 90 | 97 | 86 | R | R | R | R |
| **Gram positive** |  |  |  |  |  |  |  |  |  |  |  |  |
| *Enterococcus faecalis (VRE 1%)* | 149 | 99 | 99 | R | R | R | R | NA | 100 | R | NA | 99 |
| *Staphylococcus aureus* (MRSA 52%) | 61 | R | NA | 48 | NA | R | R | NA | 100 | 98 | 48 | 100 |
| Coagulase-negative *staphylococcus* | 26 | R | NA | 80 | R | R | R | NA | 92 | 81 | 80 | 100 |